Whole-Tumor Histogram Analysis of Multiple Diffusion Metrics for Glioma Genotyping.

Abstract

Background The isocitrate dehydrogenase (IDH) genotype and 1p/19q codeletion status are key molecular markers included in glioma pathologic diagnosis. Advanced diffusion models provide additional microstructural information. Purpose To compare the diagnostic performance of histogram features of multiple diffusion metrics in predicting glioma IDH and 1p/19q genotyping. Materials and Methods In this prospective study, participants were enrolled from December 2018 to December 2020. Diffusion-weighted imaging was performed by using a spin-echo echo-planar imaging sequence with five b values (500, 1000, 1500, 2000, and 2500 sec/mm2) in 30 directions for every b value and one b value of 0. Diffusion metrics of diffusion-tensor imaging (DTI), diffusion-kurtosis imaging (DKI), neurite orientation dispersion and density imaging (NODDI), and mean apparent propagator (MAP) were calculated, and their histogram features were analyzed in regions that included the entire tumor and peritumoral edema. Comparisons between groups were performed according to IDH genotype and 1p/19q codeletion status. Logistic regression analysis was used to predict the IDH and 1p/19q genotypes. Results A total of 215 participants (115 men, 100 women; mean age, 48 years ± 13 [standard deviation]) with grade II (n = 68), grade III (n = 35), and grade IV (n = 112) glioma were included. Among the DTI, DKI, NODDI, MAP, and total diffusion models, there were no significant differences in the areas under the receiver operating characteristic curve (AUCs) for predicting IDH mutations (AUC, 0.76, 0.82, 0.78, 0.81, and 0.82, respectively; P > .05) and 1p/19q codeletion in gliomas with IDH mutations (AUC, 0.83, 0.81, 0.82, 0.83, and 0.88, respectively; P > .05). A regression model with an R2 value of 0.84 was used for the Ki-67 labeling index and histogram features of the diffusion metrics. Conclusion Whole-tumor histogram analysis of multiple diffusion metrics is a promising approach for glioma isocitrate dehydrogenase and 1p/19q genotyping, and the performance of diffusion-tensor imaging is similar to that of advanced diffusion models. Clinical trial registration no. ChiCTR2100048119 © RSNA, 2021 Online supplemental material is available for this article. An earlier incorrect version appeared online. This article was corrected on December 14, 2021.

• Authors: Ankang Gao, Huiting Zhang, Xu Yan, Shaoyu Wang, Qianqian Chen, Eryuan Gao, Jinbo Qi, Jie Bai, Yong Zhang, Jingliang Cheng
• Journal: Radiology (Radiology) Vol. 302 Issue 3 Pg. 652-661 (03 2022) ISSN: 1527-1315 [Electronic] United States
• PMID: 34874198 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Biomarkers, Tumor
• Isocitrate Dehydrogenase

Topics

• Adolescent
• Adult
• Aged
• Biomarkers, Tumor (genetics)
• Brain Neoplasms (diagnostic imaging, genetics)
• Diffusion Tensor Imaging (methods)
• Female
• Genotype
• Glioma (diagnostic imaging, genetics)
• Humans
• Isocitrate Dehydrogenase (genetics)
• Male
• Middle Aged
• Neoplasm Grading
• Prospective Studies